1. Golchin, A., Seyedjafari, E., & Ardeshirylajimi, A. (2020). Mesenchymal stem cell therapy for COVID-19: Present or future. Stem Cell Reviews and Reports. Springer. doi:https://doi.org/10.1007/s12015-020-09973-w.
2. Cancio, M., Ciccocioppo, R., Rocco, P. R. M., Levine, B. L., Bronte, V., Bollard, C. M., … Hanley, P. J. (2020). Emerging trends in COVID-19 treatment: Learning from inflammatory conditions associated with cellular therapies. Cytotherapy. Elsevier B.V. https://doi.org/10.1016/j.jcyt.2020.04.100.
3. Liu, J., Jiao, H., & Yin, X. (2020). Engineered human mesenchymal stem cells as new vaccine platform for COVID-19. bioRxiv, 2020.06.20.163030. https://doi.org/10.1101/2020.06.20.163030
4. Adriana G. Lopes, A. S. B. F. (2018). Analysis of cost of cell therapy manufacturing: Autologous cell therapies, Part 1BioProcess International. BioProcess International, 16(3), 1–7. Retrieved from https://bioprocessintl.com/manufacturing/cell-therapies/analysis-cost-of-cell-therapy-manufacturing-autologous-cell-therapies-part-1/.
5. Adriana G. Lopes, Andrew Sinclair, B. F. (2018). Cost analysis of cell therapy manufacture: Autologous cell therapies, part 2 - BioProcess InternationalBioProcess international. Bioprocess International, 16(3), 1–7. Retrieved from https://bioprocessintl.com/manufacturing/cell-therapies/cost-analysis-of-cell-therapy-manufacturing-autologous-cell-therapies-part-2/.